Vitiligo is the commonest dyspigmentation disorder of skin and/or mucosa, with clinical manifestations of porcelain white patches. It is considered to be a multifactorial disease caused by the destruction of melanocytes. The aim of this study is to estimate serum S100B level and to evaluate its correlation with vitiligo activity and severity. Sixty three patients had vitiligo and twenty healthy volunteers as control group were included in our study. All cases were assessed for severity by VASI

more »

... core and the disease activity for the last one year. Serum S100B level was estimated in both patient and control groups. There was a highly statistically significant difference with p-value <0.001 between serum S100B level and vitiligo severity measured by VASI. There was a statistically significant difference with p-value < 0.05 between serum S100B level and vitiligo activity . In Conclusion, Serum S100B level could be used as a biochemical marker for vitiligo activity and severity. Keywords : Vitiligo , Serum S100B . J, Igoucheva O and Alexeev V (2017) : Misbalanced CXCL12 and CCL5 Chemotactic Signals in Vitiligo Onset and Progression. J Invest Dermatol ;137(5):1126-34.  {4} Lommerts JE, Teulings H-E, Ezzedine K, van Geel N, Hartmann A and Speeckaert R (2016): Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field. J Am Acad Dermatol ; 75:1198-204.  {5} Gilston BA, Skaar EP and Chazin WJ (2016): Binding of transition metals to S100 proteins. Sci China Life Sci ;59:792-801  {6} Alikhan A, Felsten LM, Daly M and Petronic-Rosic V (2011) :Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am.Acad.Dermatol; 65(3) 473-91.  {7} Tarlé RG, Nascimento LM, Mira MT, and Castro CCS (2014): Vitiligo Part 1 . Anais Brasileiros de Dermatologia; 89( 3) 461-70.  {8} Birlea SA, Spritz RA and Norris DA (2012): Vitiligo. Fitzpatrick's dermatology in general medicine; 8th ed. :792-5.  {9} Benzekri L, Ezzedine K and Gauthier Y (2013): Vitiligo Potential Repigmentation Index. Br J Dermatol ; 168(5):1143-6.  {10} Sirois CM, Jin T, Miller AL, Bertheloot D, Nakamura H and Horvath GL(2013) : RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA .J Exp Med, 210 , pp. 2447-63.  {11} Cheong KA, Noh M , Kim CH and Lee AY (2014): S100B as a potential biomarker for the detection of cytotoxicity of melanocytes. Exp Dermatol; 23: 165-71.  {12} Speeckaert R, Voet S, Hoste E and van Geel N (2017): S100B is a potential disease activity marker in non-segmental vitiligo. J Invest Dermatol ; 137: 1445-53 .